Abstract:Purpose/Objective(s) Re-irradiation (re-RT) for recurrent head and neck cancer (rHNC) after prior HNC RT is clinically challenging given prior radiation of nearby organs at risk (OARs). We describe clinical outcomes and toxicity of pencil beam scanning proton therapy (PBS-PT) for recurrent HNC, and report genomic alterations associated with patterns of failure to improve clinical decision making. Materials/Methods We performed a retrospective analysis of rHNC patients treated at a single institution with PBS-PT. Baseline demographic, disease and treatment characteristics were recorded. Clinical outcomes were estimated using the Kaplan-Meier method. Univariable (UVA) and multivariable analyses (MVA) were performed to assess patient, disease, and treatment related factors. Acute and late grade 3+ toxicities were assessed per CTCAE v5.0. Next generation sequencing (NGS) and genomic analyses were performed on available samples. Results Eighty-nine patients treated with PBS-PT for rHNC between 2016 and 2022 with a median follow-up of 12 months (range 0-71) were included. The 1- and 2-year local control rates were 80.8% (95% CI: 70.8-90.8) and 66.2% (95% CI: 50.7-81.7) and 1- and 2-year distant metastasis free survival (DMFS) were 41.0% (95% CI: 30.0-52.0) and 26.3% (95% CI: 15.7-36.9). Median overall survival (OS) was 13 months (95% CI: 9.3-16.7). On UVA and MVA, smaller gross tumor volume was associated with improved OS (HR 1.002, p=.004), DMFS (HR 1.002, p=0.004) and progression free survival (PFS) (HR 1.002, p=0.014). There were 35 late grade 3 or higher toxicity events (30.3%), including one patient that suffered late grade 5 osteoradionecrosis resulting in sepsis. Patients with higher candidate gene specific mutation burden (genes with odds-ratio >2, p<0.05) had inferior PFS. In addition, TP53, NOTCH4 and ARID1B mutations were associated with inferior DMFS (OR>2, p<0.05). Of the top 28 highly mutated genes (mutated in ≥ 3 samples in either group, odd ratio>2), TP53 was the most frequently mutated gene in DMFS alive group with Met(78%), followed by NOTCH4(52%), ARID1B (33%). please see table table1b. Conclusion Pencil beam scanning proton therapy re-irradiation is effective at achieving local control for recurrent head and neck cancer and is associated with a favorable toxicity profile. Distant metastases comprise the major failure pattern for this patient population and are associated with TP53, NOTCH4, and ARID1B somatic mutations. Validation of these findings may provide rationale for the inclusion of genomic alterations in the clinical decision process.

Radiobiology of Proton Therapy in Human Papillomavirus-Negative and Human Papillomavirus-Positive Head and Neck Cancer Cells

Patterns of Protein Expression in Human Head and Neck Cancer Cell Lines Differ after Proton Vs Photon Radiotherapy

Radiotherapy and the cellular DNA damage response: current and future perspectives on head and neck cancer treatment

Current Status and Future Directions of Proton Therapy for Head and Neck Carcinoma

Experimental Investigation of Radiobiology in Head and Neck Cancer Cell Lines As a Function of HPV Status, by MTT Assay

Radioimmunotherapy in HPV-Associated Head and Neck Squamous Cell Carcinoma

Intrinsic Radiosensitivity Is Not the Determining Factor in Treatment Response Differences between HPV Negative and HPV Positive Head and Neck Cancers

Proton therapy for head and neck cancer: expanding the therapeutic window

Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer

Investigation of DNA Damage and Cell-Cycle Distribution in Human Peripheral Blood Lymphocytes under Exposure to High Doses of Proton Radiotherapy

Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi-institutional Report on Feasibility and Early Outcomes

Inhibition of key DNA double strand break repair protein kinases enhances radiosensitivity of head and neck cancer cells to X-ray and proton irradiation

Preliminary Clinical Outcomes of Head and Neck Squamous Cell Carcinoma Treated with Particle Beam Radiation Therapy.

The Radiobiological Effects of Proton Beam Therapy: Impact on DNA Damage and Repair

An Analysis of Positron Emission Tomography Maximum Standard Uptake Value Among Patients With Head and Neck Cancer Receiving Photon and Proton Radiation

Outcomes and Genomic Landscape of Patients Treated with Re-Irradiation for Recurrent Head and Neck Cancer Using Pencil Beam Scanning Proton Therapy: The Maryland Proton Treatment Center Experience

Proton Beam Radiation Therapy for Head and Neck Malignancies

Evolution of a Paradigm Switch in Diagnosis and Treatment of HPV-Driven Head and Neck Cancer-Striking the Balance Between Toxicity and Cure

Proton Therapy in Head and Neck Cancer Treatment: State of the Problem and Development Prospects (Review)

Transitioning from conventional photon therapy to proton therapy for primary brain tumors

APR-246 & COTI-2 increase chemoradiotherapy sensitivity via ROS-induced DNA damage and ferroptosis in p53 mutant HPV negative head and neck squamous cell carcinoma